Tyrosine kinase inhibitorFDA-approvedSecond-line
Bosutinib
How it works
Blocks the BCR-ABL tyrosine kinase enzyme, which is overactive in CML cells, and also inhibits other tyrosine kinases involved in cancer growth.
Cancer types
Leukemia— BCR-ABL-positive
Efficacy
In clinical trials, around 45% of patients achieved a major cytogenetic response, with a median progression-free survival of approximately 15 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Researchers Identify Potential Way to Overcome Lung Cancer Resistance | Lung Cancer | lab-study | — | Source → |
| Lower Initial Dose of Bosutinib May Reduce Treatment Discontinuation in CML Patients | Leukemia | phase-2 | The rate of bosutinib discontinuation due to drug-related toxicities was significantly lower, at 11.4% vs. 28.2% (p = 0.015). | Source → |
| Managing Side Effects of Bosutinib for Chronic Myeloid Leukemia | Leukemia | review | — | Source → |
| Optimizing Bosutinib Dose for Chronic Myeloid Leukemia | Leukemia | phase-2 | Bosutinib treatment showed remarkable efficacy with a cumulative major molecular remission rate of 79% at month 24. | Source → |
| Tyrosine Kinase Inhibitors Affect Platelet Function in Lab Experiments | Leukemia | lab-study | — | Source → |
| New Compound Shows Promise in Treating Pancreatic Cancer | Pancreatic Cancer | lab-study | Bosutinib treatment alone/in combination with gemcitabine (Gem)/5' fluorouracil (5FU) reduced in vitro viability, migration, and colony formation in multiple PDAC cell lines as well as human PDAC organoid proliferation and growth and in vivo xenograft growth. | Source → |
| Rare Lung Injuries Linked to Cancer Treatment Drug | Leukemia | observational | — | Source → |
| Similar Heart Risks for Two Leukemia Treatments | Leukemia | observational | Ponatinib and bosutinib was associated with similar incidence and risk of CV events, including MACEs (HR: 1.02; 95% CI: 0.35, 3.01), AOEs (HR: 0.90; 95% CI: 0.43, 1.85) and VOEs (HR: 0.92; 95% CI: 0.44, 1.94). | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.